Skip Navigation


Brain Advance Access originally published online on October 10, 2007
Brain 2007 130(11):2837-2844; doi:10.1093/brain/awm238
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
130/11/2837    most recent
awm238v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (78)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pike, K. E.
Right arrow Articles by Rowe, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pike, K. E.
Right arrow Articles by Rowe, C. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

ß-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

Kerryn E. Pike1, Greg Savage1,8, Victor L. Villemagne2,3,4, Steven Ng2, Simon A. Moss1, Paul Maruff3,4,5, Chester A. Mathis6, William E. Klunk6, Colin L. Masters3,4 and Christopher C. Rowe2,7

1School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, 2Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, 3Centre for Neurosciences, University of Melbourne, 4The Mental Health Research Institute, Parkville, 5Cogstate Pty Ltd, Melbourne, Victoria, Australia, 6Departments of Radiology and Psychiatry, University of Pittsburgh, PA, USA and 7Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia

Correspondence to: Christopher Rowe, Department of Nuclear Medicine, Centre for PET, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia E-mail: christopher.rowe{at}austin.org.au

ß-amyloid (Aß) deposition is pathognomic for Alzheimer's disease (AD), but may occur in normal elderly people without apparent cognitive effect. Episodic memory impairment is an early and prominent sign of AD, but its relationship with Aß burden in non-demented persons and in AD patients is unclear. We examined this relationship using 11C-PIB-PET as a quantitative marker of Aß burden in vivo in healthy ageing (HA), mild cognitive impairment (MCI) and AD. Thirty-one AD, 33 MCI and 32 HA participants completed neuropsychological assessment and a 11C-PIB-PET brain scan. Multiple linear regression analyses were conducted relating episodic memory performance and other cognitive functions to Aß burden. Ninety-seven percent of AD, 61% of MCI and 22% of HA cases had increased cortical PIB binding, indicating the presence of Aß plaques. There was a strong relationship between impaired episodic memory performance and PIB binding, both in MCI and HA. This relationship was weaker in AD and less robust for non-memory cognitive domains. Aß deposition in the asymptomatic elderly is associated with episodic memory impairment. This finding, together with the strong relationship between PIB binding and the severity of memory impairment in MCI, suggests that individuals with increased cortical PIB binding are on the path to Alzheimer's disease. The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Aß deposition are warranted.

Key Words: memory performance; Alzheimer's disease; mild cognitive impairment; beta-amyloid; PET imaging

Abbreviations: AD, Alzheimer's disease; MCI, mild cognitive impairment; SUV, standardized uptake value

.

Received June 29, 2007. Revised August 14, 2007. Accepted September 5, 2007.

8Present address: Macquarie Centre for Cognitive Science (MACCS), Macquarie University, Sydney, NSW, Australia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
P. Bourgeat, G. Chetelat, V. L. Villemagne, J. Fripp, P. Raniga, K. Pike, O. Acosta, C. Szoeke, S. Ourselin, D. Ames, et al.
{beta}-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
Neurology, January 12, 2010; 74(2): 121 - 127.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. Tolboom, W. M. van der Flier, M. Yaqub, T. Koene, R. Boellaard, A. D. Windhorst, P. Scheltens, A. A. Lammertsma, and B.N.M. van Berckel
Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment
Neurology, December 15, 2009; 73(24): 2079 - 2085.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. C. Morris, C. M. Roe, E. A. Grant, D. Head, M. Storandt, A. M. Goate, A. M. Fagan, D. M. Holtzman, and M. A. Mintun
Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol, December 1, 2009; 66(12): 1469 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. Storandt, M. A. Mintun, D. Head, and J. C. Morris
Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-{beta} Peptide Deposition Identified With Pittsburgh Compound B: Cognitive Decline Associated With A{beta} Deposition
Arch Neurol, December 1, 2009; 66(12): 1476 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
V. L. Villemagne, S. Ataka, T. Mizuno, W. S. Brooks, Y. Wada, M. Kondo, G. Jones, Y. Watanabe, R. Mulligan, M. Nakagawa, et al.
High Striatal Amyloid {beta}-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types
Arch Neurol, December 1, 2009; 66(12): 1537 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
N. J. Cairns, M. D. Ikonomovic, T. Benzinger, M. Storandt, A. M. Fagan, A. R. Shah, L. T. Reinwald, D. Carter, A. Felton, D. M. Holtzman, et al.
Absence of PIttsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease.
Arch Neurol, December 1, 2009; 66(12): 1557 - 1562.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. He, S. Farias, O. Martinez, B. Reed, D. Mungas, and C. DeCarli
Differences in Brain Volume, Hippocampal Volume, Cerebrovascular Risk Factors, and Apolipoprotein E4 Among Mild Cognitive Impairment Subtypes
Arch Neurol, November 1, 2009; 66(11): 1393 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
A. Thathiah and B. De Strooper
G Protein-Coupled Receptors, Cholinergic Dysfunction, and A{beta} Toxicity in Alzheimer's Disease
Sci. Signal., October 20, 2009; 2(93): re8 - re8.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. J. Jagust, S. M. Landau, L. M. Shaw, J. Q. Trojanowski, R. A. Koeppe, E. M. Reiman, N. L. Foster, R. C. Petersen, M. W. Weiner, J. C. Price, et al.
Relationships between biomarkers in aging and dementia
Neurology, October 13, 2009; 73(15): 1193 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. M. Scheinin, S. Aalto, J. Koikkalainen, J. Lotjonen, M. Karrasch, N. Kemppainen, M. Viitanen, K. Nagren, S. Helin, M. Scheinin, et al.
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls
Neurology, October 13, 2009; 73(15): 1186 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. Hedden, K. R. A. Van Dijk, J. A. Becker, A. Mehta, R. A. Sperling, K. A. Johnson, and R. L. Buckner
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
J. Neurosci., October 7, 2009; 29(40): 12686 - 12694.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Okello, J. Koivunen, P. Edison, H. A. Archer, F. E. Turkheimer, K. Nagren, R. Bullock, Z. Walker, A. Kennedy, N. C. Fox, et al.
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study
Neurology, September 8, 2009; 73(10): 754 - 760.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
P. B. Rosenberg and A. E. Hillis
Biomarkers for Alzheimer's disease: ready for the next step
Brain, August 1, 2009; 132(8): 2002 - 2004.
[Full Text] [PDF]

Home page
 BrainHome page
E. C. Mormino, J. T. Kluth, C. M. Madison, G. D. Rabinovici, S. L. Baker, B. L. Miller, R. A. Koeppe, C. A. Mathis, M. W. Weiner, W. J. Jagust, et al.
Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects
Brain, May 1, 2009; 132(5): 1310 - 1323.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
C. R. Jack Jr, V. J. Lowe, S. D. Weigand, H. J. Wiste, M. L. Senjem, D. S. Knopman, M. M. Shiung, J. L. Gunter, B. F. Boeve, B. J. Kemp, et al.
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Brain, May 1, 2009; 132(5): 1355 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. J. O'Keefe, T. H. Saunder, S. Ng, U. Ackerman, H. J. Tochon-Danguy, J. G. Chan, S. Gong, T. Dyrks, S. Lindemann, G. Holl, et al.
Radiation Dosimetry of {beta}-Amyloid Tracers 11C-PiB and 18F-BAY94-9172
J. Nucl. Med., February 1, 2009; 50(2): 309 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. Britschgi and T. Wyss-Coray
Blood Protein Signature for the Early Diagnosis of Alzheimer Disease
Arch Neurol, February 1, 2009; 66(2): 161 - 165.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
R. M. Cohen
The Role of the Immune System in Alzheimer's Disease
Focus, January 1, 2009; 7(1): 28 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
C. A. Wiley, B. J. Lopresti, S. Venneti, J. Price, W. E. Klunk, S. T. DeKosky, and C. A. Mathis
Carbon 11-Labeled Pittsburgh Compound B and Carbon 11-Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease
Arch Neurol, January 1, 2009; 66(1): 60 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
H. J. Aizenstein, R. D. Nebes, J. A. Saxton, J. C. Price, C. A. Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B. E. Snitz, P. R. Houck, et al.
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol, November 1, 2008; 65(11): 1509 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. N. Gomperts, D. M. Rentz, E. Moran, J. A. Becker, J. J. Locascio, W. E. Klunk, C. A. Mathis, D. R. Elmaleh, T. Shoup, A. J. Fischman, et al.
Imaging amyloid deposition in Lewy body diseases
Neurology, September 16, 2008; 71(12): 903 - 910.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Linazasoro, C. C. Rowe, V. L. Villemagne, and C. L. Masters
IMAGING {beta}-AMYLOID BURDEN IN AGING AND DEMENTIA
Neurology, April 29, 2008; 70(18): 1649 - 1650.
[Full Text] [PDF]

Home page
 BrainHome page
C. R. Jack Jr, V. J. Lowe, M. L. Senjem, S. D. Weigand, B. J. Kemp, M. M. Shiung, D. S. Knopman, B. F. Boeve, W. E. Klunk, C. A. Mathis, et al.
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Brain, March 1, 2008; 131(3): 665 - 680.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.